217 related articles for article (PubMed ID: 37393364)
1. Molecular characteristics of microsatellite stable early-onset colorectal cancer as predictors of prognosis and immunotherapeutic response.
Lu C; Zhang X; Schardey J; Wirth U; Heinrich K; Massiminio L; Cavestro GM; Neumann J; Bazhin AV; Werner J; Kühn F
NPJ Precis Oncol; 2023 Jul; 7(1):63. PubMed ID: 37393364
[TBL] [Abstract][Full Text] [Related]
2. Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer.
Sahnane N; Magnoli F; Bernasconi B; Tibiletti MG; Romualdi C; Pedroni M; Ponz de Leon M; Magnani G; Reggiani-Bonetti L; Bertario L; Signoroni S; Capella C; Sessa F; Furlan D;
Clin Epigenetics; 2015; 7():131. PubMed ID: 26697123
[TBL] [Abstract][Full Text] [Related]
3. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
4. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
5. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
6. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
7. Identification of the molecular characteristics associated with microsatellite status of colorectal cancer patients for the clinical application of immunotherapy.
Fu J; Jin X; Chen W; Chen Z; Wu P; Xiao W; Liu Y; Deng S
Front Pharmacol; 2023; 14():1083449. PubMed ID: 36814498
[No Abstract] [Full Text] [Related]
8. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
9. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
10. [Early-onset Colorectal Cancer].
Jeong MA; Kang HW
Korean J Gastroenterol; 2019 Jul; 74(1):4-10. PubMed ID: 31344768
[TBL] [Abstract][Full Text] [Related]
11. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
Chen L; Jiang X; Li Y; Zhang Q; Li Q; Zhang X; Zhang M; Yu Q; Gao D
Clin Immunol; 2022 Apr; 237():108962. PubMed ID: 35227870
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome and Network Dissection of Microsatellite Stable and Highly Instable Colorectal Cancer.
Akbari V; Kallhor M; Mollashahi B; Movafagh A
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2445-2454. PubMed ID: 31450919
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
14. Early-onset colorectal cancer: A review of current knowledge.
Saraiva MR; Rosa I; Claro I
World J Gastroenterol; 2023 Feb; 29(8):1289-1303. PubMed ID: 36925459
[TBL] [Abstract][Full Text] [Related]
15. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer.
Kong C; Liang L; Liu G; Du L; Yang Y; Liu J; Shi D; Li X; Ma Y
Gut; 2023 Jun; 72(6):1129-1142. PubMed ID: 35953094
[TBL] [Abstract][Full Text] [Related]
16. Chr20q Amplification Defines a Distinct Molecular Subtype of Microsatellite Stable Colorectal Cancer.
Zhang B; Yao K; Zhou E; Zhang L; Cheng C
Cancer Res; 2021 Apr; 81(8):1977-1987. PubMed ID: 33619118
[TBL] [Abstract][Full Text] [Related]
17. Potential Mechanism of Immune Evasion Associated with the Master Regulator ASCL2 in Microsatellite Stability in Colorectal Cancer.
Yang Q; Huang G; Li L; Li E; Xu L
J Immunol Res; 2021; 2021():5964752. PubMed ID: 33628843
[TBL] [Abstract][Full Text] [Related]
18. Single-cell profiling of the copy-number heterogeneity in colorectal cancer.
Song S; Feng L; Xi K; Sun Z; Kong D; Luo Z; Pei W; Zhang H
Chin Med J (Engl); 2023 Mar; 136(6):707-718. PubMed ID: 36914941
[TBL] [Abstract][Full Text] [Related]
19. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
20. Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.
Alwers E; Kather JN; Kloor M; Brobeil A; Tagscherer KE; Roth W; Echle A; Amitay EL; Chang-Claude J; Brenner H; Hoffmeister M
J Pathol Clin Res; 2023 Mar; 9(2):129-136. PubMed ID: 36424650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
